Who
William A. Jones Jr.
Director
Company insider
Files Form 4 as: Director, Apogee Therapeutics; Director, Apnimed; Director, Annexon; Chief Commercial Officer, NewAmsterdam Pharma Company; Director, Akili; CCO-Migraine & Common Disease, Biohaven Pharmaceutical Holding Co; Vice President, Nitromed.
In numbers
- Trades disclosed
- 72
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $2.3M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 16 Aug 2006
- Last trade
- 3 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —34,824 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,370 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,461 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,370 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,461 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,657 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,657 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —34,824 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —44,477 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,477 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —44,477 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,477 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,477 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,477 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,657 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,657 at $0.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,461 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ANNX Annexonoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.